Download the best practice from our 2nd Session
Although crucial to the success of program and projects, few biopharma companies develop robust processes to identify and mitigate risk. For our 2nd Session, our group debated the purpose and benefits of Risk Management and Scenario Planning in biopharma programs and projects. We addressed questions like:
Why doing RM & SP made sense? Is the effort worth the benefit?
Were these practices significant to PMs in their current roles? Why or why not?
For PMs that were doing it today: how did they approach it at their organizations?
For PMs who were not doing it: How else were they managing execution uncertainties?
Following the group discussion, we came up with a best practice approach for doing risk management and scenario planning in the context of biopharma programs and projects.
The session was lead by Tyson Bertmaring, Director of Program Management Office at Momenta Pharmaceuticals.